GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback